Şahin M.Miskioğlu M.Inanır I.Akar H.Neşe N.Temiz P.Aydoğdu İ.2024-07-222024-07-22202113007777http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13621[No abstract available]EnglishAll Open Access; Gold Open AccessAged, 80 and overAntineoplastic Agents, ImmunologicalBrentuximab VedotinFemaleHumansLymphoma, Large-Cell, AnaplasticSkinSkin NeoplasmsTreatment Outcomeanastrozolebrentuximab vedotinlactate dehydrogenasebrentuximab vedotinimmunological antineoplastic agentagedanaplastic large cell lymphomabone lesionbone marrow biopsybreast carcinomabreast diseasebreast imaging reporting and data systembreast nodulebreast tumorcancer regressioncase reportcell infiltrationclinical articledaily life activityerythemaerythematous plaqueface injuryfemalefrailtyhemoglobin blood levelhistopathologyhumanLetterloss of appetitemammographymonotherapymultiple cycle treatmentpositron emission tomography-computed tomographyskin defecttreatment responseulcervery elderlyweaknessanaplastic large cell lymphomapathologyskinskin tumortreatment outcomeCutaneous anaplastic large-cell lymphoma with dramatic response to brentuximab vedotin; [Brentuximab vedotine dramatik yanıtlı kutanöz anaplastik büyük hücreli lenfoma]Letter10.4274/tjh.galenos.2020.2020.0512